• Mashup Score: 51

    KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in OS as a neoadjuvant and adjuvant treatment versus pre-operative chemotherapy for NSCLC Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) met its dual primary endpoint of overall survival (OS). At a pre-specified interim analysis, KEYTRUDA plus chemotherapy before surgery (neoadjuvant), followed by resection and KEYTRUDA as a single agent after surgery (adjuvant), demonstrated a statistically significant and clinically meaningful improvement in OS compared to neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in these patients. The safety profile of KEYTRUDA was consistent with that observed in previously

    Tweet Tweets with this article
    • JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!! -NSCLC Stage II, IIIA or IIIB (T3-4N2) -Pembrolizumab is the first PD1 drug with OS in a perioperative setting! -Initially presented at #ASCO23 -Update at #ESMO23 https://t.co/rvGAQCu1yI @OncoAlert @myESMO @OncBrothers https://t.co/unbjYU8Atv https://t.co/vGyoOx3Oh4

    • 🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 https://t.co/gJtIzuB4xV https://t.co/CPDSHjQwOg

  • Mashup Score: 1

    Author links open overlay panel Teresa Amaral MD, PhD a b, Oltin Tiberiu Pop MD, PhD c, Eftychia Chatziioannou MD a, Tobias Sinnberg Dr rer nat a b d, Heike Niessner Dr rer nat a b, Jing Zhao MSc e, Sandra Stephanie Ring PhD f, Markus Joerger MD, PhD g, Christopher Schroeder MD h, Sorin Armeanu-Ebinger Dr rer nat h, Antonio Cozzio MD, Dr sc nat i, Ulrike Leiter MD a, Ioannis Thomas MD a, Wolfram Jochum MD j, Claus Garbe MD a, Stephan Forchhammer MD a, Mitchell Levesque PhD k, Joanna Mangana MD k, Michael

    Tweet Tweets with this article
    • Does #EGFR play a role in #melanoma? We looked for #EGFR expression in treatment-naive melanoma #metastases & our results show that EGFR expression is associated with #relapse in #patients w/ melanoma receiving #adjuvant PD-1 based ICI https://t.co/qIQdaNc4a5 https://t.co/eAcLKz5a2f

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • Read this article to earn #CME Credit: A team of researchers designed a research study to help determine the effectiveness of #adjuvant #chemotherapy after #neoadjuvant chemotherapy (NAC) followed by surgery specifically for #PDAC patients. Learn more: https://t.co/lceRkR1Xim https://t.co/XQFFRyLci7

  • Mashup Score: 0
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • Read this article to earn #CME Credit: A team of researchers designed a research study to help determine the effectiveness of #adjuvant #chemotherapy after #neoadjuvant chemotherapy (NAC) followed by surgery specifically for #PDAC patients. Learn more: https://t.co/lceRkR1Xim https://t.co/PIA8s2VSZD